Wu Jingjing, Fu Jiaping, Zhang Mingzhi, Liu Delong
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Department of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang Province, China.
J Hematol Oncol. 2015 Aug 1;8:96. doi: 10.1186/s13045-015-0188-3.
Monoclonal antibodies against CD20 molecule have been leading the revolution of lymphoma treatment. In addition to monoclonal antibodies against CD20 and CD30, novel agents of immunotherapeutics in clinical development are being developed and are rapidly migrating to clinical application. One area of active development is NK cell activators, such as AFM13. This review will highlight the latest development of AFM13 as the first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
抗CD20分子的单克隆抗体引领了淋巴瘤治疗的革命。除了抗CD20和抗CD30单克隆抗体外，正在开发临床阶段的新型免疫治疗药物，并迅速向临床应用迈进。一个积极发展的领域是NK细胞激活剂，如AFM13。本综述将重点介绍AFM13作为一流的四价双特异性抗CD30/CD16A抗体用于NK细胞介导的免疫治疗的最新进展。
Zotero 插件
